Continuous intravenous infusion of ghrelin does not stimulate feeding in tumor-bearing rats

Nutrition and Cancer

Volumn 60, Issue 1, 2008, Pages 75-90

  Chance, William T ^a,b   Dayal, Ramesh ^a   Friend, Lou Ann ^b   Thomas, Ingrid ^b   Sheriff, Sulaiman ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; APPETITE STIMULANT; FAT; GHRELIN; MESSENGER RNA; MUSCLE PROTEIN; NEUROPEPTIDE; NEUROPEPTIDE Y; PEPTIDE; PROOPIOMELANOCORTIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; BODY FAT; CANCER THERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TARGETING; FEEDING; FOOD INTAKE; HYPOTHALAMUS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT PLANNING; TUMOR; WEIGHT GAIN;

AGOUTI-RELATED PROTEIN; ANIMALS; AREA UNDER CURVE; BASE SEQUENCE; CACHEXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; GHRELIN; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS, EXPERIMENTAL; NEUROPEPTIDE Y; RANDOM ALLOCATION; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

AGOUTI; RATTUS;

EID: 38749132869     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701753016     Document Type: Article

References (57)

1. Morrison SD: Control of food intake in cancer cachexia: a challenge and a tool. Physiol Behav 17, 705-714, 1976.
2. Anker SD and Sharma R: The syndrome of cardiac cachexia. Cardiology 85, 51-66, 2002.
3. Hussain R, Lobo MA, Inam B, Khan A, Qureshi AF, et al.: Pneumonia perceptions and management: an ethnographic study in urban squatter settlements of Karachi, Pakistan. Soc Sci Med 45, 991-1004, 1997.
4. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, et al.: Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115, 1659-1665, 2005.
5. Leon LR, White AA, and Kluger MJ: Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol Regul Integr Comp Physiol 275, R269-R277, 1998.
6. Grunfeld C: The wasting syndrome in AIDS: mechanisms and implications. Nutrition 11-12, 853-863, 1998.
7. DeWys WD, Begg C, and Lavin PT: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69, 491-497, 1980.
8. Lanzotti VJ, Thomas DR, Boyle LE, Smith TL, Gehan EA, et al.: Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 39, 303-313, 1977.
9. Warren S: The immediate causes of death in cancer. Am J Med Sci 184, 610-615, 1932.
10. Costa G: Cachexia, the metabolic component of neoplastic diseases. Cancer Res 37, 2327-2335, 1977.
11. Shamberger RC, Brennan MF, Goodgame JT, Lowry SF, Maher MM, et al.: A prospective, randomized study of adjuvant parenteral nutrition in the treatment of sarcomas: results of metabolic and survival studies. Surgery 96, 1-12, 1984.
12. Argiles JM, Almemdro V, Busquets S, and Lopez-Soriano FJ: The pharmacological treatment of cachexia. Curr Drug Targets 5, 265-277, 2004.
13. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, et al.: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141, 4325-4328, 2000.
14. Nakazato M, Marakami N, Date Y, Kojima M, Matsuo H, et al.: A role for ghrelin in the central regulation of feeding. Nature 409, 194-198, 2001.
15. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, et al.: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992-5995, 2001.
16. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, et al.: Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 50, 2438-2443, 2001.
17. Wisse BE, Fravo RS, Schwartz MW, and Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142, 3292-3301, 2001.
18. Chance WT, Sheriff S, Dayal R, and Balasubramaniam A: Refractory hypothalamic α-MSH satiety and AGRP feeding systems in rats bearing MCA sarcomas. Peptides 24, 1909-1919, 2003.
19. Tschop M, Smiley DL, and Helman ML: Ghrelin induces adiposity in rodents. Nature 407, 908-913, 2000.
20. Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada T, et al.: Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Comm 301, 275-279, 2003.
21. Neary N, Small C, Wren A, Lee J, Druce M, et al.: Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metabol 89, 2832-2836, 2004.
22. Chance WT, Cao L, Nelson JL, Foley-Nelson T, and Fischer JE: Acivicin reduces tumor growth during total parenteral nutrition (TPN). Surgery 102, 386-394, 1987.
23. Chance WT, Cao L, Nelson JL, Foley-Nelson T, and Fischer JE: Reversal of biochemical aberrations following tumor resection in rats. Am J Surg 155, 124-130, 1988.
24. Chance WT, Balasubramaniam A, and Sheriff S: Neuropeptide Y and cancer anorexia. Curr Med Chem-CNS Agents 3, 127-139, 2003.
25. Chance WT, Sheriff S, Kasckow JW, Regmi A, and Balasubramaniam A: NPY messenger RNA is increased in medial hypothalamus of anorectic tumor-bearing rats. Regul Pept 75/76, 347-353, 1998.
26. Kane JK, Hwang Y, Konu O, Loughlin SE, Leslie FM, et al.: Regulation of Homer and group I metabotropic glutamate receptors by nicotine. Eur J Neurosci 21, 1145-1154, 2005.
27. Tichopad A, Dilger M, Schwartz G, and Pfaffl MW: Standardized determination of real-time PCR efficiency from a single reaction set-up. Nucleic Acids Res 31, e122, 2003.
28. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, et al.: Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540-2547, 2001.
29. Thompson NM, Davies JS, Mode A, Houston PA, and Wells T: Pattern-dependent suppression of growth hormone (GH) pulsatility by ghrelin and GH-releasing peptide-6 in moderately GH-deficient rats. Endocrinology 144, 4859-4867, 2003.
30. Kanamoto N, Akamizu T, Hosoda H, Hataya Y, Ariyasu H, et al.: Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. J Clin Endocrinol Metabol 86, 4984-4990, 2001.
31. Ishimaru M, Yoshizawa-Kumagaye K, Kubo S, Kiyani T, Chino N, et al.: Stability of the O-octanoyl group of rat ghrelin during chemical synthesis: counter-ion-dependent alteration of an ester bond breakage. Lett Pept Sci 10, 41-50, 2003.
32. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, et al.: Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 9, 774-778, 2003.
33. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, et al.: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90, 2929-2936, 2005.
34. Wang W, Anderson M, Iresjo BM, Lonnroth C, and Lundholm K: Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol 28, 1393-1400, 2006.
35. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, et al.: Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related peptide. Endocrinology 145, 2607-2612, 2004.
36. Sahu A, Kalra PS, and Kalra SP: Food deprivation and ingestion induce reciprocal changes in Neuropeptide Y concentrations in the paraventricular nucleus. Peptides 9, 83-89, 1988.
37. Kalra SP, Dube MG, Sahu A, Phelps CP, and Kalra PS: Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 88, 10931-10935, 1991.
38. Plata-Salaman CR, Ilyin SE, and Gayle D: Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor. Am J Physiol 275, R566-R573, 1998.
39. Bing C, Taylor S, Tisdale MJ, and Williams G: Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 79, 1004-1012, 2001.
40. Jensen PB, Blume NB, Mikkelsen JD, Larsen PJ, Jensen HI, et al.: Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA in the hypothalamic arcuate nucleus. J Clin Invest 101, 503-510, 1998.
41. Nara-ashizawa N, Tsukada T, Maruyama K, Akiyama Y, Kajimura N, et al.: Response of hypothalamic NPY mRNAs to a negative energy balance is less sensitive in cachectic mice bearing human tumor cells. Nutr Cancer 41, 111-118, 2001.
42. Chance WT, Balasubramaniam A, Thompson H, Mohapatra B, Ramo J, et al.: Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 17, 797-801, 1996.
43. 1 receptor in arcuate and paraventricular nuclei of anorectic tumor-bearing rats. Peptides, in press, 2006.
44. Richard D: Involvement of corticotropin-releasing factor in the control of food intake and energy expenditure. Ann New York Acad Sci 771, 155-172, 1995.
45. Spina M, Merlo-Pich E, Chan RKW, Basso AM, Rivier J, et al.: Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 273, 1561-1564, 1996.
46. Heinrichs SC, Menzaghi F, Pich EM, Hauger RL, and Koob GF: corticotrophin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. Brain Res 611, 18-24, 1993.
47. Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dullo A, et al.: Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett 408, 39-42, 1997.
48. Muzzin P, Boss O, and Giacobino JP: Uncoupling protein 3: its possible biological role and mode of regulation in rodents and humans. J Bioenerg Biomembr 31, 467-473, 1999.
49. Sanchis D, Busquets S, Alvarez B, Ricquier D, Lopez-Soriano FJ, et al.: Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett 436, 415-418, 1998.
50. Bing C, Brown M, King P, Collins P, Tisdale MJ, et al.: Increased gene expression of brown fat uncoupling protein (UCP) 1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 60, 2405-2410, 2000.
51. Collins P, Bing C, McCulloch P, and Williams G: Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Brit J Cancer 86, 372-375, 2002.
52. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, et al.: Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116, 1983-1993, 2006.
53. Tsubone T, Masaki T, Katsuragi I, Tanaka K, Kakuma T, et al.: Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice. Regul Pept 130, 97-103, 2005.
54. Muccioli G, Pons N, Ghe C, Catapano F, Ranata R, et al.: Ghrelin and desacyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 498, 27-35, 2004.
55. Yasuda T, Masaki T, Kakuma T, and Yoshimatsu H: Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. Neurosci Lett 349, 75-78, 2003.
56. Barazzoni R, Bosutti A, Stebel M, Cattin MR Roder E, et al.: Ghrelin regulates mitochondrial-oipoid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Amer J Physiol Endocrinol Metab 288, E228-E235, 2005.
57. Thompson NM, Gill DAS, Davies R, Loveridge N, Houston PA, et al.: Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145, 234-242, 2004.